Francesca Finelli

Dr. Francesca Finelli


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2023 in Cancers
Verified
Journal Article
Open access
PDF file
FSFABIANO SVOLACCHIA
FABIANO SVOLACCHIA
SBSergio Brongo
Sergio Brongo
ACAlessia Catalano
Alessia Catalano
CACeccarini Agostino
Ceccarini Agostino
LSLorenzo Svolacchia
Lorenzo Svolacchia
FGFederica Giuzio
Federica Giuzio
In this review, we summarize the most used natural products as useful adjuvants in BC by clarifying how these products may play a critical role in the prevention, treatment and progression of this disease. BC is the leading cancer, in terms of incidence, that affects women. The epidemiology and pathophysiology of BC were widely reported. Inflammation and cancer are known to influence each other in several tumors. In the case of BC, the inflammatory component precedes the development of the neoplasm through a slowly increasing and prolonged inflammation that also favors its growth. BC therapy involves a multidisciplinary approach comprising surgery, radiotherapy and chemotherapy. There are numerous observations that showed that the effects of some natural substances, which, in integration with the classic protocols, can be used not only for prevention or integration in order to prevent recurrences and induce a state of chemoquiescence but also as chemo- and radiosensitizers during classic therapy.

15 January 2024 in Medicina
Verified
Journal Article
Open access
PDF file
FFFrancesca Finelli
Francesca Finelli
ACAlessia Catalano
Alessia Catalano
MLMichele De Lisa
Michele De Lisa
GFGiuseppe Andrea Ferraro
Giuseppe Andrea Ferraro
SGSabino Genovese
Sabino Genovese
Carmela SaturninoCarmela Saturnino
Carmela Saturnino
The study of migraine is based on the complexity of the pathology, both at the pathophysiological and epidemiological levels. Although it affects more than a billion people worldwide, it is often underestimated and underreported by patients. Migraine must not be confused with a simple headache; it is a serious and disabling disease that causes considerable limitations in the daily life of afflicted people, including social, work, and emotional effects. Therefore, it causes a daily state of suffering and discomfort. It is important to point out that this pathology not only has a decisive impact on the quality of life of those who suffer from it but also on their families and, more generally, on society as a whole. The clinical picture of migraine is complex, with debilitating unilateral or bilateral head pain, and is often associated with characteristic symptoms such as nausea, vomiting, photophobia, and phonophobia. Hormonal, environmental, psychological, dietary, or other factors can trigger it. The present review focuses on the analysis of the physiopathological and pharmacological aspects of migraine, up to the correct dietary approach, with specific nutritional interventions aimed at modulating the symptoms. Based on the symptoms that the patient experiences, targeted and specific therapy is chosen to reduce the frequency and severity of migraine attacks. Specifically, the role of calcitonin gene-related peptide (CGRP) in the pathogenesis of migraine is analyzed, along with the drugs that effectively target the corresponding receptor. Particularly, CGRP receptor antagonists (gepants) are very effective drugs in the treatment of migraine, given their high diffusion in the brain. Moreover, following a ketogenic diet for only one or two months has been demonstrated to reduce migraine attacks. In this review, we highlight the diverse facets of migraine, from its physiopathological and pharmacological aspects to prevention and therapy.

9 February 2026 in Applied Sciences
Verified
Journal Article
Open access
PDF file
INIlaria Nigro
Ilaria Nigro
Maria Francesca ArmentanoMaria Francesca Armentano
Maria Francesca Armentano
Anna CarusoAnna Caruso
Anna Caruso
HEHussein El-Kashef
Hussein El-Kashef
FGFederica Giuzio
Federica Giuzio
Carmela SaturninoCarmela Saturnino
Carmela Saturnino
This study focuses on the rational design and synthesis of new pyrrolidinone derivatives aimed at inhibiting the ACE2 receptor, a key entry point for SARS-CoV-2. Building on structural insights from known inhibitors like MLN-4760, five compounds featuring a pyrrolidinone core, with some incorporating indole rings, were synthesized and characterized. Their inhibitory activity against ACE2 was evaluated in vitro, with compound 4 showing the most promising results, further confirmed through cytotoxicity assays and molecular docking studies. Docking analysis revealed favorable binding interactions within the ACE2 active site, supporting the potential of compound 4 as a therapeutic agent. These findings provide a foundation for future in vivo studies and highlight the potential development of novel therapeutics targeting ACE2-related diseases, including COVID-19.